首页|LncRNA XIST和miR-141-3p在肾结石患者血清中的表达及临床意义

LncRNA XIST和miR-141-3p在肾结石患者血清中的表达及临床意义

扫码查看
目的 探讨肾结石患者中血清长链非编码RNA X染色体失活特异转录本(Ln-cRNA XIST)、miR-141-3p的表达水平及其临床意义.方法 选取2018年4月至2022年12月在开滦总医院林西医院诊治的100例肾结石患者作为肾结石组,并选取同期100例健康体检者作为对照组.比较两组患者的血清LncRNA XIST、miR-141-3p、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、骨桥蛋白(OPN)水平;分析肾结石患者的血清LncRNA XIST、miR-141-3p表达水平与IL-1β、TNF-α、OPN的相关性,血清LncRNA XIST表达水平与miR-141-3p的相关性;记录肾结石患者治疗后21 d内发生不良预后情况,并根据预后情况将其分为预后不良组(24例)和预后良好组(76例),比较两组血清LncRNA XIST、miR-141-3p、IL-1β、TNF-α、OPN水平;分析肾结石患者预后的影响因素.结果 与对照组相比,肾结石组患者的血清LncRNA XIST、IL-1β、TNF-α、OPN水平均升高,而miR-141-3p表达水平降低(均P<0.05).Pearson法分析结果显示,肾结石患者血清LncRNA XIST表达水平与IL-1 β、TNF-α、OPN呈正相关(r=0.507、0.396、0.472,均 P<0.05),miR-141-3p 表达水平与 IL-1β、TNF-α、OPN 呈负相关(r=-0.483、-0.414、-0.458,均P<0.05).肾结石患者的血清LncRNA XIST表达水平与miR-141-3p呈负相关(r=-0.463,P<0.05).与预后良好组相比,预后不良组的血清LncRNA XIST、IL-1β、TNF-α、OPN 水平均升高,而 miR-141-3p 表达水平降低(均 P<0.05).LncRNA XIST、IL-1β、TNF-α、OPN是影响肾结石患者预后的危险因素(均P<0.05),且miR-141-3p是影响肾结石患者预后的保护因素(P<0.05).结论 肾结石患者的血清LncRNA XIST表达上调,miR-141-3p表达下调,LncRNA XIST、miR-141-3p可能是早期诊断肾结石、评估患者预后的指标.
Expression and clinical significance of LncRNA XIST and miR-141-3p in serum of patients with kidney stones
Objective To investigate the expression levels and clinical significance of serum long non-coding RNA(LncRNA)X inactive specific transcript(LncRNA XIST)and microRNA-141-3p(miR-141-3p)in patients with kidney stones.Methods A total of 100 patients with kidney stones admitted to Kailuan General Hospital Linxi Hospital from April 2018 to December 2022 taken as the kid-ney stones group,and 100 healthy subjects were included as the control group.The levels of serum Ln-cRNA XIST,miR-141-3p,interleukin-1 β(IL-1 β),tumor necrosis factor-α(TNF-α)and osteopontin(OPN)in the kidney stones group and the control group were compared.The correlation of serum Ln-cRNA XIST and miR-141-3p expression levels with IL-1β,TNF-α and OPN in patients with kidney stones,and the correlation between serum LncRNA XIST expression levels and miR-141-3p were ana-lyzed.The adverse prognosis of patients with kidney stones within 21 days after retrograde intrarenal surgery was recorded,and the patients were divided into a poor prognosis group(24 cases)and a good prognosis group(76 cases)according to the prognosis,the general data and serum levels of LncRNA XIST,miR-141-3p,IL-1β,TNF-α and OPN in patients with kidney stones with different prognosis were compared.The influencing factors of the prognosis of patients with kidney stones were analyzed.Results Compared with the control group,the serum levels of LncRNA XIST,IL-1β,TNF-α and OPN were increased in the kidney stone group,while the expression level of miR-141-3p was de-creased(all P<0.05).The results of Pearson analysis showed that the expression level of serum Ln-cRNA XIST in patients with kidney stones was positively correlated with IL-1β,TNF-α and OPN(r=0.507,0.396,0.472,all P<0.05).The expression level of miR-141-3p was negatively correlated with IL-1 β,TNF-α and OPN(r=-0.483,-0.414,-0.458,all P<0.05).The expression level of serum LncRNA XIST in patients with kidney stones was negatively correlated with miR-141-3p(r=-0.463,P<0.05).Compared with the good prognosis group,the levels of serum LncRNA XIST,IL-1 β,TNF-α and OPN in the poor prognosis group were increased,while the expression level of miR-141-3p was decreased(all P<0.05).LncRNA XIST,IL-1β,TNF-α and OPN were risk factors af-fecting the prognosis of patients with kidney stones(all P<0.05),and miR-141-3p was a protective factor affecting the prognosis of patients with kidney stones(P<0.05).Conclusions The expression of serum LncRNA XIST is up-regulated and the expression of miR-141-3p is down-regulated in patients with kidney stones.LncRNA XIST and miR-141-3p may be auxiliary indicators for early diagnosis of kidney stones and evaluation of prognosis of patients.

Kidney CalculimiR-141-3pLncRNA XIST

李强、刘晶、张国民、王亮、刘志飞

展开 >

开滦总医院林西医院泌尿外科,唐山 063100

唐山市人民医院泌尿外科,唐山 063000

肾结石 miR-141-3p LncRNA XIST

河北省医学科学研究课题计划

20220216

2024

国际泌尿系统杂志
中华医学会,湖南省医学会

国际泌尿系统杂志

CSTPCD
影响因子:0.414
ISSN:1673-4416
年,卷(期):2024.44(5)
  • 8